BR112017010346A2 - homodímero, composição farmacêutica, uso de um homodímero, e, métodos para tratamento ou prevenção de uma doença ou condição e para produção de uma composição farmacêutica. - Google Patents
homodímero, composição farmacêutica, uso de um homodímero, e, métodos para tratamento ou prevenção de uma doença ou condição e para produção de uma composição farmacêutica.Info
- Publication number
- BR112017010346A2 BR112017010346A2 BR112017010346A BR112017010346A BR112017010346A2 BR 112017010346 A2 BR112017010346 A2 BR 112017010346A2 BR 112017010346 A BR112017010346 A BR 112017010346A BR 112017010346 A BR112017010346 A BR 112017010346A BR 112017010346 A2 BR112017010346 A2 BR 112017010346A2
- Authority
- BR
- Brazil
- Prior art keywords
- homodimer
- pharmaceutical composition
- disease
- treating
- preventing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1420445.7A GB2532426B (en) | 2014-11-18 | 2014-11-18 | Therapeutic homodimer and uses thereof |
| PCT/EP2015/076712 WO2016079066A1 (en) | 2014-11-18 | 2015-11-16 | Therapeutic homodimer and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017010346A2 true BR112017010346A2 (pt) | 2018-05-15 |
Family
ID=52248504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017010346A BR112017010346A2 (pt) | 2014-11-18 | 2015-11-16 | homodímero, composição farmacêutica, uso de um homodímero, e, métodos para tratamento ou prevenção de uma doença ou condição e para produção de uma composição farmacêutica. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20180015136A1 (https=) |
| EP (1) | EP3220939B1 (https=) |
| JP (1) | JP6693969B2 (https=) |
| KR (1) | KR20170083064A (https=) |
| CN (1) | CN107206048B (https=) |
| AU (1) | AU2015348673B2 (https=) |
| BR (1) | BR112017010346A2 (https=) |
| CA (1) | CA2967140C (https=) |
| CY (1) | CY1124859T1 (https=) |
| DK (1) | DK3220939T3 (https=) |
| EA (1) | EA034876B1 (https=) |
| ES (1) | ES2886001T3 (https=) |
| GB (1) | GB2532426B (https=) |
| IL (1) | IL252349B (https=) |
| MA (1) | MA40969A (https=) |
| MX (1) | MX392248B (https=) |
| SG (1) | SG11201703757PA (https=) |
| WO (1) | WO2016079066A1 (https=) |
| ZA (1) | ZA201703580B (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0516527D0 (en) * | 2005-08-11 | 2005-09-21 | Arpi Matossian Rogers | Peptides |
| KR101527334B1 (ko) * | 2005-08-11 | 2015-06-09 | 알피 마토씨안-로저스 | 자가면역 질병의 치료 및 진단용 ｔｃｒ-ｖ-베타 관련 펩티드 |
-
2014
- 2014-11-18 GB GB1420445.7A patent/GB2532426B/en active Active
-
2015
- 2015-11-16 MA MA040969A patent/MA40969A/fr unknown
- 2015-11-16 EP EP15795157.5A patent/EP3220939B1/en active Active
- 2015-11-16 JP JP2017544990A patent/JP6693969B2/ja active Active
- 2015-11-16 BR BR112017010346A patent/BR112017010346A2/pt not_active Application Discontinuation
- 2015-11-16 AU AU2015348673A patent/AU2015348673B2/en active Active
- 2015-11-16 ES ES15795157T patent/ES2886001T3/es active Active
- 2015-11-16 SG SG11201703757PA patent/SG11201703757PA/en unknown
- 2015-11-16 WO PCT/EP2015/076712 patent/WO2016079066A1/en not_active Ceased
- 2015-11-16 EA EA201791103A patent/EA034876B1/ru unknown
- 2015-11-16 CN CN201580073803.2A patent/CN107206048B/zh active Active
- 2015-11-16 CA CA2967140A patent/CA2967140C/en active Active
- 2015-11-16 DK DK15795157.5T patent/DK3220939T3/da active
- 2015-11-16 US US15/527,904 patent/US20180015136A1/en not_active Abandoned
- 2015-11-16 MX MX2017006278A patent/MX392248B/es unknown
- 2015-11-16 KR KR1020177014562A patent/KR20170083064A/ko not_active Abandoned
-
2017
- 2017-05-17 IL IL252349A patent/IL252349B/en unknown
- 2017-05-24 ZA ZA2017/03580A patent/ZA201703580B/en unknown
-
2020
- 2020-11-10 US US17/094,192 patent/US20210060118A1/en not_active Abandoned
-
2021
- 2021-09-30 CY CY20211100850T patent/CY1124859T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3220939T3 (da) | 2021-08-30 |
| MX392248B (es) | 2025-03-24 |
| JP2018500386A (ja) | 2018-01-11 |
| IL252349A0 (en) | 2017-07-31 |
| AU2015348673A1 (en) | 2017-06-01 |
| CA2967140A1 (en) | 2016-05-26 |
| CY1124859T1 (el) | 2022-11-25 |
| HK1223287A1 (zh) | 2017-07-28 |
| EA201791103A1 (ru) | 2017-09-29 |
| ZA201703580B (en) | 2018-08-29 |
| GB2532426A (en) | 2016-05-25 |
| GB201420445D0 (en) | 2014-12-31 |
| CA2967140C (en) | 2021-09-21 |
| AU2015348673B2 (en) | 2019-01-03 |
| US20210060118A1 (en) | 2021-03-04 |
| CN107206048B (zh) | 2021-02-26 |
| KR20170083064A (ko) | 2017-07-17 |
| CN107206048A (zh) | 2017-09-26 |
| EP3220939B1 (en) | 2021-06-30 |
| MX2017006278A (es) | 2017-10-24 |
| EA034876B1 (ru) | 2020-04-01 |
| GB2532426B (en) | 2016-11-02 |
| WO2016079066A1 (en) | 2016-05-26 |
| EP3220939A1 (en) | 2017-09-27 |
| NZ731655A (en) | 2020-09-25 |
| SG11201703757PA (en) | 2017-06-29 |
| IL252349B (en) | 2022-02-01 |
| MA40969A (fr) | 2021-04-28 |
| JP6693969B2 (ja) | 2020-05-13 |
| ES2886001T3 (es) | 2021-12-16 |
| US20180015136A1 (en) | 2018-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000588A (es) | Moduladores de la somatostatina y usos de los mismos. | |
| CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
| BR112017009807A2 (pt) | métodos e formulações para tratamento de doenças oculares vasculares | |
| SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| DOP2016000226A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112017003346B8 (pt) | Derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| MX391536B (es) | Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas. | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| DOP2016000212A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| BR112018011607A2 (pt) | composto, composição farmacêutica, métodos para tratamento de um distúrbio relacionado ao estrogênio e de um câncer, para fabricação de um medicamento para uso terapêutico no tratamento de um distúrbio e para prevenção de um distúrbio relacionado ao estrogênio, uso de um composto ou de uma composição farmacêutica, e, processo para preparação de um produto farmacêutico. | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| MX394222B (es) | Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). | |
| CO7111276A2 (es) | Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met | |
| CY1119957T1 (el) | Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος | |
| CL2018001085A1 (es) | Derivados de indolin-2-ona | |
| BR112015006656A8 (pt) | composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos | |
| MX2017015292A (es) | Composicion para tratar lesiones cerebrales. | |
| BR112018067554A2 (pt) | formulações de testosterona e métodos de tratamento com as mesmas | |
| EP4420722A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| BR112017026834A2 (pt) | composição compreendendo vitaminas b e vitaminas c e seu uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |